The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer

This publication has 42 references indexed in Scilit:

• Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125
  Molecular Medicine Reports, 2015
• Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 2015
• ROMA, an algorithm for ovarian cancer
  Clinica Chimica Acta, 2015
• Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer
  International Journal of Endocrinology, 2013
• Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women
  Gynecologic Oncology, 2012
• Benefits and risks of ovarian function and reproduction for cancer development and prevention
  Gynecological Endocrinology, 2011
• Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer
  Journal of Cancer Research and Clinical Oncology, 2011
• Potential markers that complement expression of CA125 in epithelial ovarian cancer
  Gynecologic Oncology, 2005
• Production of CA125 by human lung cancer cell lines
  Clinical and Experimental Medicine, 2004
• Screening for Ovarian Cancer
  Annals of Internal Medicine, 1994